Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 SOHO 2026Correlation Between IL-8 and TNF-Alpha and Overall Survival in Imetelstat-Treated Patients With Myelofibrosis Relapsed or Refractory to a Janus-Associated Kinase Inhibitor in the IMbark Trial September 9, 2026 SOHO 2026Early Real-World Use and Hematologic Outcomes With Imetelstat in Patients With Myelodysplastic Syndromes: Insights From a United States Community Oncology Chart Review September 9, 2026 SOHO 2026Updated Analysis of Overall Survival With Imetelstat in Relapsed or Refractory Myelofibrosis from IMbark Versus Real-World Data, and Assessment of Real-World Treatment Patterns: Updated Post Hoc Analysis With Extended Follow Up September 9, 2026 EHA 2026Real-world Outcomes of Imetelstat: Interrogating Safety, Efficacy and Predictors of Response in Heavily Pretreated Lower-Risk MDS Patients June 12, 2026 ASCO 2026Updated protocol: IMproveMF, a Phase 1b trial of imetelstat+ruxolitinib in patients with intermediate-1/2 or high-risk myelofibrosis June 1, 2026 ASCO 2026Updated analysis of overall survival with imetelstat in relapsed/refractory myelofibrosis versus real-world data, and assessment of real-world treatment patterns June 1, 2026 Blood NeoplasiaIncreased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial April 16, 2026 Blood Cancer JournalAssociation between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes April 7, 2026 Haematologica Early ViewImetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study January 22, 2026 Nature LeukemiaModulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat January 12, 2026
SOHO 2026Correlation Between IL-8 and TNF-Alpha and Overall Survival in Imetelstat-Treated Patients With Myelofibrosis Relapsed or Refractory to a Janus-Associated Kinase Inhibitor in the IMbark Trial September 9, 2026
SOHO 2026Early Real-World Use and Hematologic Outcomes With Imetelstat in Patients With Myelodysplastic Syndromes: Insights From a United States Community Oncology Chart Review September 9, 2026
SOHO 2026Updated Analysis of Overall Survival With Imetelstat in Relapsed or Refractory Myelofibrosis from IMbark Versus Real-World Data, and Assessment of Real-World Treatment Patterns: Updated Post Hoc Analysis With Extended Follow Up September 9, 2026
EHA 2026Real-world Outcomes of Imetelstat: Interrogating Safety, Efficacy and Predictors of Response in Heavily Pretreated Lower-Risk MDS Patients June 12, 2026
ASCO 2026Updated protocol: IMproveMF, a Phase 1b trial of imetelstat+ruxolitinib in patients with intermediate-1/2 or high-risk myelofibrosis June 1, 2026
ASCO 2026Updated analysis of overall survival with imetelstat in relapsed/refractory myelofibrosis versus real-world data, and assessment of real-world treatment patterns June 1, 2026
Blood NeoplasiaIncreased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial April 16, 2026
Blood Cancer JournalAssociation between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes April 7, 2026
Haematologica Early ViewImetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study January 22, 2026
Nature LeukemiaModulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat January 12, 2026
